Moreover, IL-33 treatment increases CCL2 and CXCL2 production in NFATc3+/+ macrophages, but not in NFATc3+/- mice, suggesting that NFATc3 regulates pulmonary fibrosis by regulating CCL2 and CXCL2 expression in macrophages (93). The gene discussed is NFATC3; the disease is pulmonary fibrosis.